Silicon Labs Reports Third Quarter 2026 Results

SILICON LABORATORIES INC. (SLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 Silicon Labs Reports Third Quarter 2026 Results Wireless IoT leader delivers $251 million in revenue and strong earnings growth AUSTIN, Texas – November 10, 2026 – Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for

Event · Earnings
Original reporting
Published Nov 10, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLAB
Bullish
high confidence
Mentioned
$SLAB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLABBullishHigh
01

Why it matters

The earnings beat and record medical revenue are likely to boost the stock, though the pending TI merger adds uncertainty.

02

Market read

First‑report earnings with solid growth in a key semiconductor niche, influencing both sector sentiment and merger‑related speculation.

03

What to watch

inventory levels are near record lows, which may constrain short‑term sales despite demand

Relevance 8/10Novelty 8/10Timing: post-market today
AlphAI · Earnings readSLAB · Q3 2026 · ended 2026-10-03

Silicon Labs third-quarter 2026 revenue rose 22% year-over-year to $251 million, GAAP operating income turned positive at $8 million, and non-GAAP diluted EPS was $1.05. Guidance is suspended pending the Texas Instruments acquisition.

✓Strong quarter

Revenue grew 22% year-over-year and 10% sequentially, medical reached a new quarterly record, GAAP operating income was $7,951 thousand against a loss of $(12,342) thousand a year earlier, and non-GAAP EPS was $1.05. Offsetting factors are the suspended forward guidance, the pending acquisition by Texas Instruments, and a nine-month GAAP net loss with lower nine-month operating cash flow.

Revenue
$251M
22% y/y · 10% q/q
Industrial & Commercial
$141M
20% y/y
Gross margin · GAAP
60.8%
EPS · non-GAAP
$1.05
228% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenues (Q3 2026, three months ended October 3, 2026)GAAP$250.9M10%22%
Gross profit (Q3 2026)GAAP$152.6M––
Gross margin (Q3 2026)GAAP60.8%––
Cost of revenues (Q3 2026)GAAP$98.31M––
Research and development expense (Q3 2026)GAAP$93.17M––
Selling, general and administrative expense (Q3 2026)GAAP$51.45M––
Operating expenses (Q3 2026)GAAP$144.6M––
Operating income (loss) (Q3 2026)GAAP$7.95M––
Interest income and other, net (Q3 2026)GAAP$3.19M––
Interest expense (Q3 2026)GAAP−$226K––
Income (loss) before income taxes (Q3 2026)GAAP$10.91M––
Provision for income taxes (Q3 2026)GAAP$2.06M––
Net income (loss) (Q3 2026)GAAP$8.85M––
Diluted earnings (loss) per share (Q3 2026)GAAP$0.26––
Basic earnings (loss) per share (Q3 2026)GAAP$0.27––
Diluted earnings per share (Q3 2026)non-GAAP$1.05–228%
Gross profit (Q3 2026)non-GAAP$153.0M––
Gross margin (Q3 2026)non-GAAP61.0%––
Research and development expense (Q3 2026)non-GAAP$75.26M––
Selling, general and administrative expense (Q3 2026)non-GAAP$37.58M––
Operating expenses (Q3 2026)non-GAAP$112.8M––
Operating income (Q3 2026)non-GAAP$40.20M––
Operating margin (Q3 2026)non-GAAP16.0%––
Net income (Q3 2026)non-GAAP$35.39M––
Revenues (nine months ended October 3, 2026)GAAP$692.6M––
Gross profit (nine months ended October 3, 2026)GAAP$420.3M––
Cost of revenues (nine months ended October 3, 2026)GAAP$272.3M––
Research and development expense (nine months ended October 3, 2026)GAAP$276.8M––
Selling, general and administrative expense (nine months ended October 3, 2026)GAAP$163.3M––
Operating expenses (nine months ended October 3, 2026)GAAP$440.0M––
Operating income (loss) (nine months ended October 3, 2026)GAAP−$19.80M––
Interest income and other, net (nine months ended October 3, 2026)GAAP$9.3M––
Interest expense (nine months ended October 3, 2026)GAAP−$709K––
Income (loss) before income taxes (nine months ended October 3, 2026)GAAP−$11.21M––
Provision for income taxes (nine months ended October 3, 2026)GAAP$6.43M––
Net income (loss) (nine months ended October 3, 2026)GAAP−$17.64M––
Diluted earnings (loss) per share (nine months ended October 3, 2026)GAAP$(0.53)––
Net cash provided by operating activities (nine months ended October 3, 2026)GAAP$37.20M––
Purchases of property and equipment (nine months ended October 3, 2026)GAAP−$28.47M––
Cash and cash equivalents (at October 3, 2026)GAAP$423.0M––
Total assets (at October 3, 2026)GAAP$1.34B––
Total stockholders' equity (at October 3, 2026)GAAP$1.13B––

Segments

SegmentRevenueq/qy/y
Industrial & CommercialThe filing reports the revenue and growth figure without a stated driver. The CEO cites broad-based growth across many end applications for total revenue.$141M–20%
Home & LifeThe filing reports the revenue and growth figure without a stated driver. The CEO cites broad-based growth across many end applications for total revenue.$110M–24%
MedicalThe company attributes the record quarter to continued known customer ramps, per the CEO.Not disclosed in dollars in the filing; described as a new quarterly record48%More than 300%

Capital returns

  • The filing reports no share repurchase or dividend activity for the quarter or nine months.
  • Payment of taxes withheld for vested stock awards was $(28,710) thousand for the nine months ended October 3, 2026, against $(14,907) thousand a year earlier.
  • Proceeds from the issuance of common stock were $7,761 thousand for the nine months ended October 3, 2026, against $8,147 thousand a year earlier.

What drove it

  • Per the CEO, revenue growth was broad-based across many end applications, and medical reached another record quarter as known customer ramps continued.
  • Per the CEO, earnings significantly outpaced revenue growth, which the company attributes to strong operational execution.
  • The filing states that bookings imply a healthy demand environment.
  • The filing states that distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter.
  • Medical revenue increased 48% sequentially and more than 300% year-over-year, per the filing.

Concerns

  • Forward-looking guidance has been suspended because of the pending acquisition of Silicon Labs by Texas Instruments.
  • The filing identifies the pending merger, including the ability to complete it within the expected time frame or at all, as a risk factor.
  • Nine-month GAAP net loss was $(17,638) thousand, and nine-month GAAP diluted EPS was $(0.53).
  • Nine-month net cash provided by operating activities fell to $37,198 thousand from $87,358 thousand a year earlier.
  • Inventories rose to $133,391 thousand at October 3, 2026, from $95,566 thousand at January 3, 2026.
  • The filing lists the current global memory chip shortage, trade policy and tariffs, and geopolitical risks among factors that could affect results.

What to watch

  • Timing and completion of the Texas Instruments acquisition, and any disruption to operations or restrictions during its pendency.
  • Whether the company resumes forward-looking guidance, and the level of any future outlook if it does.
  • Sustainability of medical revenue following the record quarter and the pace of the known customer ramps.
  • Movement in inventories and operating cash flow relative to the nine-month figures reported.
  • Whether the company's stated backlog and design-win ramps translate into the continued revenue growth and earnings expansion described by the CEO.

Balance sheet and cash flow

  • Cash and cash equivalents were $423,013 thousand at October 3, 2026, against $364,222 thousand at January 3, 2026.
  • Short-term investments were $16,828 thousand at October 3, 2026, against $79,400 thousand at January 3, 2026.
  • Inventories were $133,391 thousand at October 3, 2026, against $95,566 thousand at January 3, 2026.
  • Accounts receivable, net were $79,966 thousand at October 3, 2026, against $64,513 thousand at January 3, 2026.
  • Total liabilities were $210,772 thousand at October 3, 2026, against $174,899 thousand at January 3, 2026.
  • Net cash provided by operating activities was $37,198 thousand for the nine months ended October 3, 2026, against $87,358 thousand a year earlier.
  • Inventory change within operating cash flow was $(37,828) thousand for the nine months, against $23,316 thousand a year earlier.
  • Maturities of marketable securities were $62,309 thousand for the nine months, against $22,598 thousand a year earlier.
  • Proceeds from capital-related government incentives were $8,705 thousand for the nine months, with no comparable amount in the prior-year period.
  • Net cash provided by investing activities was $42,542 thousand for the nine months, against $(20,802) thousand a year earlier.

Analysis

Silicon Labs reported third-quarter 2026 revenue of $250,892 thousand, up 22% year-over-year from $205,999 thousand, with the CEO stating revenue rose 10% sequentially. The filing attributes the growth to broad-based strength across end applications and a new quarterly record in medical revenue, which the company said reflects continued known customer ramps. Segment figures printed are Industrial & Commercial at $141 million (up 20% year-over-year) and Home & Life at $110 million (up 24% year-over-year). Medical is described as up 48% sequentially and more than 300% year-over-year, but its dollar revenue is not printed.

Profitability moved sharply. GAAP gross margin was 60.8% and non-GAAP gross margin was 61.0%. GAAP operating expenses were $144,627 thousand and GAAP operating income was $7,951 thousand, compared with a loss of $(12,342) thousand a year earlier. GAAP net income was $8,851 thousand, against a net loss of $(9,936) thousand. GAAP diluted EPS was $0.26 and non-GAAP diluted EPS was $1.05. The company describes the earnings expansion as the result of operational execution. The prior-year non-GAAP EPS figure is not printed, so the 228% increase the filing cites cannot be checked against a base in the document.

On a nine-month basis, revenue was $692,581 thousand against $576,558 thousand, and GAAP operating loss narrowed to $(19,797) thousand from $(67,289) thousand. Nine-month GAAP net loss remained at $(17,638) thousand. Operating cash flow was $37,198 thousand, down from $87,358 thousand, and inventories rose to $133,391 thousand at October 3, 2026 from $95,566 thousand at January 3, 2026. Capital expenditure was $(28,472) thousand for the nine months against $(19,942) thousand a year earlier. Cash and cash equivalents were $423,013 thousand at quarter end.

The filing states that distributor inventory declined to a multi-year low and end customer inventory was near record lows, and that bookings imply a healthy demand environment. Those points are the company's own characterization and are not quantified in the release.

The most important item for an investor is that the company has suspended forward-looking guidance because of the pending acquisition by Texas Instruments. No outlook for the fourth quarter or any other period is provided, so the reader cannot compare the results with a prior outlook. The CEO's forward statements about revenue growth and earnings expansion are framed by the risk factors listed in the filing, which include the merger itself, the memory chip shortage, and trade policy.

Management, verbatim

We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued.

Matt Johnson, President and Chief Executive Officer

Earnings significantly outpaced revenue growth, a result of strong operational execution by the team.

Matt Johnson, President and Chief Executive Officer

Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.

Matt Johnson, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Forward guidance for Q4 2026 or any future period: suspended by the company due to the pending acquisition by Texas Instruments.
  • Prior-year quarter non-GAAP diluted EPS: not printed, so the 228% increase cannot be tied to a base figure.
  • Prior-year quarter GAAP and non-GAAP gross margin figures: not printed in the prior-year column.
  • Prior-quarter (Q2 2026) revenue and other line items in dollar terms: the 10% sequential change is stated, but the prior-quarter figures are not printed.
  • Medical revenue in dollar terms: described as a record and growing by stated percentages, but the dollar amount is not printed.
  • Prior-year and prior-quarter dollar revenue for Industrial & Commercial and Home & Life: only current-quarter dollar values and year-over-year percentages are printed.
  • Year-over-year percentage changes for gross profit, operating expenses, operating income and net income: not printed.
  • Nine-month year-over-year percentage changes for all lines: not printed.
  • Nine-month non-GAAP results: not printed in the filing.
  • Quarterly operating cash flow, free cash flow, and capital expenditure for Q3 2026 alone: only nine-month cash flow figures are printed.
  • Share repurchase and dividend data: not reported in the filing.
  • Balance sheet prior-quarter figures (June 2026): not printed; balance sheet comparatives are at January 3, 2026.
  • Total liabilities and equity prior-period comparison at the same quarter-end in 2025: not printed.
  • Stock price reaction and analyst consensus: not in the documents.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Silicon Labs filed an 8‑K reporting its third‑quarter 2026 results, the first public disclosure of these numbers.

Company-level read

Ticker impact

$SLABBullishHigh confidence
Context

Silicon Labs reported Q3 2026 revenue of $251M, 22% YoY growth and GAAP EPS of $0.26, marking a turnaround from a loss a year ago.

Expected impact

likely upward pressure as the market prices in the earnings beat and robust growth

Evidence & confidence

Revenue and earnings both exceeded prior year, with record medical segment growth, which typically drives short-term buying.

Market effects

reinforces strength in the low‑power wireless IoT semiconductor segment

supports US semiconductor equities after earnings season

highlights continued global demand for IoT connectivity across industrial and medical applications

Counterpoint

Pending acquisition by Texas Instruments could delay execution and introduce integration risk, tempering upside

Key entities

  • Silicon Labs Inc.

    NASDAQ‑listed provider of low‑power wireless IoT solutions

  • Texas Instruments

    Potential acquirer of Silicon Labs

Every SLAB earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$SLABMed

Silicon Labs Swings To Q3 Profit

Silicon Labs (SLAB) reported Q3 net income of $8.9M ($0.26/share), reversing a year-ago loss. Revenue rose 22% to $250.9M, with all segments growing. Adjusted EPS was $1.05, up 228% YoY. The company suspended guidance due to its pending acquisition by Texas Instruments.